{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:53:04Z","timestamp":1781153584176,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T00:00:00Z","timestamp":1485993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T00:00:00Z","timestamp":1485993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Constitutive NF-E2-related factor 2 (Nrf2, NFE2L2) activation has been recently reported to play a pivotal role in enhancing cell survival and resistance to anticancer drugs in many tumors. Wogonin had strong reversal potency via reduction of <jats:italic>Nrf2<\/jats:italic> mRNA in Adriamycin (ADR)-induced resistant human chronic myelogenous leukemia (CML) K562\/A02, but the mechanism of reduction of <jats:italic>Nrf2<\/jats:italic> mRNA was still unclear. In this study, we aimed to delineate the mechanism by which Wogonin suppressed transcription of <jats:italic>Nrf2<\/jats:italic> in resistant CML cells and further evaluate the reversal effects of Wogonin on the established animal models. Data indicated that Wogonin suppressed transcription of <jats:italic>Nrf2<\/jats:italic> by NF-\u03baB inactivation. Wogonin inhibited the binding of p65 to Nrf2 by suppression of the \u03baB-binding activity. Further research revealed the \u03baB2 site was responsible for the decreased Nrf2 by Wogonin in resistant K562 cells. Furthermore, reduction of pY705-Stat3 was involved in inhibition of the binding of p65 to Nrf2 by Wogonin. <jats:italic>In vivo<\/jats:italic>, Wogonin potentiated the inhibitory effect of ADR on leukemia development by suppressing pY705-Stat3 and Nrf2 signaling. In summary, these results demonstrated Wogonin could combat chemoresistance effectively through inhibiting Nrf2 via Stat3\/NF-\u03baB signaling, and supported that Wogonin can be developed into an efficient natural sensitizer for resistant human myelogenous leukemia.<\/jats:p>","DOI":"10.1038\/srep39950","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T10:23:01Z","timestamp":1486030981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["RETRACTED ARTICLE: Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3\/NF-\u03baB inactivation"],"prefix":"10.1038","volume":"7","author":[{"given":"Xuefen","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoliang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyi","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,2]]},"reference":[{"key":"BFsrep39950_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2174\/1389203023380521","volume":"3","author":"K Ejendal","year":"2002","unstructured":"Ejendal, K. & Hrycyna, C. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. Current Protein and Peptide Science. 3, 503\u2013511 (2002).","journal-title":"Current Protein and Peptide Science"},{"key":"BFsrep39950_CR2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2174\/15680096113139990084","volume":"13","author":"A Cagnetta","year":"2013","unstructured":"Cagnetta, A. et al. Evaluating Treatment Response of Chronic Myeloid Leukemia: Emerging Science and Technology. Curr Cancer Drug Targets. 13, 779\u2013790 (2013).","journal-title":"Curr Cancer Drug Targets"},{"key":"BFsrep39950_CR3","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","volume":"104","author":"J Cortes","year":"2004","unstructured":"Cortes, J., Brien, S. O. & Kantarjian, H. Discontinuation of imatinib therapy after achieving a molecular response. Blood. 104, 2204\u20132205 (2004).","journal-title":"Blood."},{"key":"BFsrep39950_CR4","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland, M. et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 107, 4532\u20134539 (2006).","journal-title":"Blood."},{"key":"BFsrep39950_CR5","first-page":"2093","volume":"5","author":"S Chu","year":"2005","unstructured":"Chu, S. et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. 15 5, 2093\u20132100 (2005).","journal-title":"15"},{"key":"BFsrep39950_CR6","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas, J., Wang, L., Clark, R. E. & Pirmohamed, M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 104, 3739\u20133745 (2004).","journal-title":"Blood."},{"key":"BFsrep39950_CR7","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","volume":"109","author":"Y Wang","year":"2007","unstructured":"Wang, Y. et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation. Blood. 109, 2147\u20132155 (2007).","journal-title":"Blood."},{"key":"BFsrep39950_CR8","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre, M. E. et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification. Science. 293, 876 (2001).","journal-title":"Science."},{"key":"BFsrep39950_CR9","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","volume":"16","author":"SG Willis","year":"2005","unstructured":"Willis, S. G. et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 16, 2128 (2005).","journal-title":"Blood."},{"key":"BFsrep39950_CR10","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","volume":"106","author":"M Tallman","year":"2005","unstructured":"Tallman, M., Gilliland, D. & Rowe, J. Drug therapy for acute myeloid leukemia. Blood. 106, 1154\u20131163 (2005).","journal-title":"Blood."},{"key":"BFsrep39950_CR11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1146\/annurev.biochem.78.070907.102750","volume":"78","author":"B Skaug","year":"2009","unstructured":"Skaug, B., Jiang, X. & Chen, Z. The role of ubiquitin in NF-kappaB regulatory pathways. Annual Review of Biochemistry. 78, 769\u2013796 (2009).","journal-title":"Annual Review of Biochemistry"},{"key":"BFsrep39950_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1089\/ars.2005.7.385","volume":"7","author":"M Kobayashi","year":"2005","unstructured":"Kobayashi, M. & Yamamoto, M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxidants and Redox Signalling. 7, 385\u2013394 (2005).","journal-title":"Antioxidants and Redox Signalling"},{"key":"BFsrep39950_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/14728220903431069","volume":"14","author":"Y Lin","year":"2010","unstructured":"Lin, Y., Bai, L., Chen, W. & Xu, S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets. 14, 45\u201355 (2010).","journal-title":"Expert Opin Ther Targets"},{"key":"BFsrep39950_CR14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/MPA.0b013e3181c31314","volume":"39","author":"YB Hong","year":"2010","unstructured":"Hong, Y. B. et al. Nuclear Factor (Erythroid-Derived 2)-Like 2 Regulates Drug Resistance in Pancreatic Cancer Cells. Pancreas. 39, 463\u2013472 (2010).","journal-title":"Pancreas."},{"key":"BFsrep39950_CR15","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/cas.12478","volume":"105","author":"HQ Yan","year":"2014","unstructured":"Yan, H. Q. et al. Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated\/NF-kappaB pathway activation Cancer Science. 105, 1220\u20131227 (2014).","journal-title":"Cancer Science."},{"key":"BFsrep39950_CR16","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1172\/JCI25790","volume":"116","author":"RK Thimmulappa","year":"2006","unstructured":"Thimmulappa, R. K. et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. Journal of Clinical Investigation. 116, 984\u2013995 (2006).","journal-title":"Journal of Clinical Investigation"},{"key":"BFsrep39950_CR17","doi-asserted-by":"publisher","first-page":"725174","DOI":"10.1155\/2008\/725174","volume":"2008","author":"W Jin","year":"2008","unstructured":"Jin, W. et al. Disruption of Nrf2 enhances upregulation of nuclear factor-kappaB activity, proinflammatory cytokines, and intercellular adhesion molecule-1 in the brain after traumatic brain injury. Mediators of Inflammation. 2008, 725174 (2008).","journal-title":"Mediators of Inflammation"},{"key":"BFsrep39950_CR18","first-page":"713","volume":"1783","author":"GH Liu","year":"2008","unstructured":"Liu, G. H., Qu, J. & Shen, X. NF-\u03baB\/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK. BBA - Molecular Cell Research 1783, 713\u2013727 (2008).","journal-title":"BBA - Molecular Cell Research"},{"key":"BFsrep39950_CR19","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1182\/blood-2012-04-422121","volume":"120","author":"SA Rushworth","year":"2012","unstructured":"Rushworth, S. A. et al. The high Nrf2 expression in human acute myeloid leukemia is driven by NF-\u03baB and underlies its chemo-resistance.. Blood. 120, 5188\u20135198 (2012).","journal-title":"Blood."},{"key":"BFsrep39950_CR20","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1182\/blood-2007-07-104042","volume":"111","author":"SA Rushworth","year":"2008","unstructured":"Rushworth, S. A. & MacEwan, D. J. HO-1 underlies resistance of AML cells to TNF-induced apoptosis. Blood. 111, 3793\u20133801 (2008).","journal-title":"Blood."},{"key":"BFsrep39950_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.tibs.2008.12.008","volume":"34","author":"JD Hayes","year":"2009","unstructured":"Hayes, J. D. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends in Biochemical Sciences. 34, 176\u2013188 (2009).","journal-title":"Trends in Biochemical Sciences"},{"key":"BFsrep39950_CR22","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1158\/0008-5472.CAN-09-3407","volume":"70","author":"SA Rushworth","year":"2010","unstructured":"Rushworth, S. A., Bowles, K. M., Raninga, P. & MacEwan, D. J. NF-kappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction. Cancer Research. 70, 2973 (2010).","journal-title":"Cancer Research."},{"key":"BFsrep39950_CR23","first-page":"44675","volume":"23","author":"DA Bloom","year":"2003","unstructured":"Bloom, D. A. & Jaiswal, A. K. Phosphorylation of Nrf2 at Ser40 by Protein Kinase C in Response to Antioxidants Leads to the Release of Nrf2 from INrf2, but Is Not Required for Nrf2 Stabilization\/Accumulation in the Nucleus and Transcriptional Activation of Antioxidant Response Element-mediated NAD(P)H:Quinone Oxidoreductase-1 Gene Expression. JBC Papers in Press 23, 44675\u201344682 (2003).","journal-title":"JBC Papers in Press"},{"key":"BFsrep39950_CR24","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.freeradbiomed.2009.03.023","volume":"46","author":"CM Mahaffey","year":"2009","unstructured":"Mahaffey, C. M. et al. Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma. Free Radical Biology and Medicine. 46, 1650\u20131657 (2009).","journal-title":"Free Radical Biology and Medicine"},{"key":"BFsrep39950_CR25","first-page":"5","volume":"2011","author":"SA Rushworth","year":"2011","unstructured":"Rushworth, S. A., Bowles, K. M. & MacEwan, D. J. High Basal Nuclear Levels of Nrf2 in Acute Myeloid Leukemia Reduces Sensitivity to Proteasome Inhibitors. Cancer Research 2011, 5 (2011).","journal-title":"Cancer Research"},{"key":"BFsrep39950_CR26","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1158\/1535-7163.MCT-09-0589","volume":"9","author":"P Zhang","year":"2010","unstructured":"Zhang, P. et al. Loss of Kelch-Like ECH-Associated Protein 1 Function in Prostate Cancer Cells Causes Chemoresistance and Radioresistance and Promotes Tumor Growth Molecular Cancer Therapeutics. 9, 336 (2010).","journal-title":"Molecular Cancer Therapeutics"},{"key":"BFsrep39950_CR27","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1158\/0008-5472.CAN-10-0713","volume":"70","author":"T Jiang","year":"2010","unstructured":"Jiang, T. et al. High Levels of Nrf2 Determine Chemoresistance in Type II Endometrial Cancer. Cancer Research. 70, 5486 (2010).","journal-title":"Cancer Research."},{"key":"BFsrep39950_CR28","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1053\/j.gastro.2008.06.082","volume":"135","author":"T Shibata","year":"2008","unstructured":"Shibata, T. et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology. 135, 1358\u20131368 (2008).","journal-title":"Gastroenterology."},{"key":"BFsrep39950_CR29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.bcp.2014.05.007","volume":"90","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. CXCL12\/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562\/ADM cells Biochemical Pharmacology. 90, 212\u2013225 (2014).","journal-title":"Biochemical Pharmacology."},{"key":"BFsrep39950_CR30","doi-asserted-by":"publisher","first-page":"33761","DOI":"10.1074\/jbc.M604748200","volume":"281","author":"MH Kweon","year":"2006","unstructured":"Kweon, M. H., Mustafa, A. V., Lee, J. S. & Mukhtar, H. Constitutive Overexpression of Nrf2-dependent Heme Oxygenase-1 in A549 Cells Contributes to Resistance to Apoptosis Induced by Epigallocatechin 3-Gallate. Journal of Biological Chemistry. 281, 33761\u201333772 (2006).","journal-title":"Journal of Biological Chemistry"},{"key":"BFsrep39950_CR31","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1073\/pnas.1014275108","volume":"108","author":"D Ren","year":"2011","unstructured":"Ren, D. et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proceedings Of The National Academy Of Sciences Of The United States Of America. 108, 1433\u20131438 (2011).","journal-title":"Proceedings Of The National Academy Of Sciences Of The United States Of America"},{"key":"BFsrep39950_CR32","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.freeradbiomed.2011.03.008","volume":"50","author":"X Tang","year":"2011","unstructured":"Tang, X. et al. Luteolin Inhibits NRF2 Leading to Negative Regulation of the NRF2\/ARE Pathway and Sensitization of Human Lung Carcinoma A549 Cells to Therapeutic Drugs. Free Radical Biology and Medicine. 50, 1599 (2011).","journal-title":"Free Radical Biology and Medicine"},{"key":"BFsrep39950_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1527-3458.2005.tb00266.x","volume":"11","author":"MC Tai","year":"2005","unstructured":"Tai, M. C., Tsang, S. Y., Lawrence, Y. F. & Chang, H. X. Therapeutic potential of wogonin: a naturally occurring flavonoid. CNS Drug Reviews. 11, 141\u2013150 (2005).","journal-title":"CNS Drug Reviews"},{"key":"BFsrep39950_CR34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bcp.2014.09.008","volume":"92","author":"X Xu","year":"2014","unstructured":"Xu, X. et al. Wogonin reverses multi-drug resistance of human myelogenous leukemia K562\/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2\/ARE signaling pathway. Biochemical Pharmacology. 92, 220\u2013234 (2014).","journal-title":"Biochemical Pharmacology."},{"key":"BFsrep39950_CR35","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0006-2952(02)01347-3","volume":"64","author":"KM Hui","year":"2002","unstructured":"Hui, K. M. et al. Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi. Biochemical Pharmacology. 64, 1415\u20131424 (2002).","journal-title":"Biochemical Pharmacology."},{"key":"BFsrep39950_CR36","first-page":"333","volume":"16","author":"CZ Yang","year":"1995","unstructured":"Yang, C. Z. et al. Multidrug resistance in leukemic cell line K562\/A02 induced by doxorubicin. Zhongguo Yao Li Xue Bao. 16, 333\u2013337 (1995).","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"BFsrep39950_CR37","first-page":"22","volume":"38","author":"HL Zhu","year":"2007","unstructured":"Zhu, H. L., Liu, T., Meng, W. T. & Jia, Y. Q. Establishment of an imatinib resistance cell line K562R and its resistant principia. Journal Of Sichuan University. Medical Science Edition 38, 22\u201326 (2007).","journal-title":"Journal Of Sichuan University. Medical Science Edition"},{"key":"BFsrep39950_CR38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature10189","volume":"475","author":"GM DeNicola","year":"2011","unstructured":"DeNicola, G. M. et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 475, 106\u2013109 (2011).","journal-title":"Nature."},{"key":"BFsrep39950_CR39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccr.2009.02.015","volume":"15","author":"H Lee","year":"2009","unstructured":"Lee, H. et al. Persistently Activated Stat3 Maintains Constitutive NF-\u03baB Activity in Tumors. Cancer Cell. 15, 283\u2013293 (2009).","journal-title":"Cancer Cell."},{"key":"BFsrep39950_CR40","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.fct.2007.09.082","volume":"46","author":"A Gopalakrishnan","year":"2008","unstructured":"Gopalakrishnan, A. & Kong, T. Anticarcinogenesis by dietary phytochemicals: cytoprotection by Nrf2 in normal cells and cytotoxicity by modulation of transcription factors NF-kappa B and AP-1 in abnormal cancer cells. Food and Chemical Toxicology. 46, 1257\u20131270 (2008).","journal-title":"Food and Chemical Toxicology"},{"key":"BFsrep39950_CR41","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1089\/ars.2005.7.1648","volume":"7","author":"G Shen","year":"2005","unstructured":"Shen, G., Jeong, W. S., Hu, R. & Kong, A. N. Regulation of Nrf2, NF-kappaB, and AP-1 signaling pathways by chemopreventive agents. Antioxidants and Redox Signalling. 7, 1648\u20131663 (2005).","journal-title":"Antioxidants and Redox Signalling"},{"key":"BFsrep39950_CR42","doi-asserted-by":"publisher","first-page":"e1283","DOI":"10.1038\/cddis.2014.221","volume":"5","author":"J Yao","year":"2014","unstructured":"Yao, J. et al. NF-\u03baB and Nrf2 signaling pathways contribute to wogonin-mediated inhibition of inflammation-associated colorectal carcinogenesis. Cell Death Dis. 5, e1283 (2014).","journal-title":"Cell Death Dis"},{"key":"BFsrep39950_CR43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1165\/rcmb.2006-0340TR","volume":"36","author":"J Alam","year":"2007","unstructured":"Alam, J. & Cook, J. L. How many transcription factors does it take to turn on the heme oxygenase-1 gene? American Journal of Respiratory Cell and Molecular Biology. 36, 166\u2013174 (2007).","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"BFsrep39950_CR44","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.molcel.2006.01.013","volume":"21","author":"B Padmanabhan","year":"2006","unstructured":"Padmanabhan, B. et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Molecular Cell. 21, 689\u2013700 (2006).","journal-title":"Molecular Cell."},{"key":"BFsrep39950_CR45","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.wneu.2011.09.055","volume":"80","author":"R Grossman","year":"2013","unstructured":"Grossman, R. & Ram, Z. The Dark Side of Nrf2. World Neurosurgery 80, 284\u2013286 (2013).","journal-title":"World Neurosurgery"},{"key":"BFsrep39950_CR46","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature04870","volume":"441","author":"M Karin","year":"2006","unstructured":"Karin, M. Nuclear factor-kappaB in cancer development and progression. Nature. 441, 431\u2013436 (2006).","journal-title":"Nature."},{"key":"BFsrep39950_CR47","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/bjc.2013.752","volume":"110","author":"LH Wang","year":"2014","unstructured":"Wang, L. H. et al. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-\u03baB and MAPK\/HO-1 signalling British Journal of Cancer. 110, 341\u2013352 (2014).","journal-title":"British Journal of Cancer"},{"key":"BFsrep39950_CR48","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/sj.onc.1207173","volume":"23","author":"ZM Liu","year":"2004","unstructured":"Liu, Z. M. et al. Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells. Oncogene. 23, 503\u2013513 (2004).","journal-title":"Oncogene."},{"key":"BFsrep39950_CR49","doi-asserted-by":"publisher","first-page":"26071","DOI":"10.1074\/jbc.274.37.26071","volume":"274","author":"J Alam","year":"1999","unstructured":"Alam, J. et al. Nrf2, a CapnCollar transcription factor, regulates induction of the heme oxygenase-1 gene. The Journal of Biological Chemistry. 274, 26071\u201326078 (1999).","journal-title":"The Journal of Biological Chemistry"},{"key":"BFsrep39950_CR50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1126\/science.1140485","volume":"317","author":"WE Naugler","year":"2007","unstructured":"Naugler, W. E. et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 317, 121\u2013124 (2007).","journal-title":"Science"},{"key":"BFsrep39950_CR51","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ccr.2008.12.018","volume":"15","author":"M Kortylewski","year":"2009","unstructured":"Kortylewski, M. et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell. 15, 114 (2009).","journal-title":"Cancer Cell."},{"key":"BFsrep39950_CR52","doi-asserted-by":"publisher","first-page":"39776","DOI":"10.1074\/jbc.M605707200","volume":"281","author":"R Faraonio","year":"2006","unstructured":"Faraonio, R. et al. p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. Journal of Biological Chemistry. 281, 39776\u201339784 (2006).","journal-title":"Journal of Biological Chemistry"}],"updated-by":[{"DOI":"10.1038\/s41598-022-13462-0","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"record-id":"37545"},{"DOI":"10.1038\/s41598-021-91964-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000}},{"DOI":"10.1038\/s41598-022-13462-0","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep39950.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep39950","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep39950.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:53:29Z","timestamp":1671843209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep39950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,2]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,2,8]]}},"alternative-id":["BFsrep39950"],"URL":"https:\/\/doi.org\/10.1038\/srep39950","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,2]]},"assertion":[{"value":"4 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Editors\u2019 Note: The editorial team is currently investigating concerns that have been raised relating to the reliability of data presented in this manuscript. We will update readers once we have further information and all parties have been given an opportunity to respond in full.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-022-13462-0","URL":"https:\/\/doi.org\/10.1038\/s41598-022-13462-0","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":11,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":12,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":13,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-021-91964-z","URL":"https:\/\/doi.org\/10.1038\/s41598-021-91964-z","order":14,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39950"}}